Investigational drug · Phase 2
Personalized Neoantigen Peptide Vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Advanced Cancer, Recurrent Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
55
Any phase or sponsor naming "Personalized Neoantigen Peptide Vaccine"
First trial start
2022
Nov 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Personalized Neoantigen Peptide Vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Advanced Cancer
- Recurrent Cancer
- Neoantigen-Specific Immunotherapy
- Personalized Cancer Vaccine
- Cancer
- Solid Tumor, Adult
Approved drugs for the same conditions: Oncology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Personalized Neoantigen Peptide Vaccine" as an intervention, largest first.
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
Seattle Project CorporationIndustry
NCT05141721 · 700 participants (planned) · Start Feb 12, 2022 · Primary completion Mar 2027
Drug: GRT-C901; GRT-R902 and 4 more · For: Colorectal Neoplasms
Sites: Gilbert, Arizona; Springdale, Arkansas; Los Angeles, California · 43 sites in all
Mayo ClinicAcademic, hospital or other
NCT05269381 · 138 participants (planned) · Start Mar 31, 2022 · Primary completion Mar 31, 2028
Drug: Cyclophosphamide; Neoantigen Peptide Vaccine and 2 more · For: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8 and 98 more
Sites: Jacksonville, Florida
- A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsEnrolling by invitation
Jaime Leandro Foundation for Therapeutic Cancer VaccinesAcademic, hospital or other
NCT05741242 · 136 participants (planned) · Start Nov 30, 2022 · Primary completion Jan 2027
Drug: Personalized Synthetic Long Peptide Vaccine · For: Cancer; Solid Tumor
Sites: Beverly Hills, California; San Francisco, California; Santa Monica, California · 6 sites in all
Instituto de Medicina RegenerativaIndustry
NCT05475106 · 100 participants (planned) · Start May 12, 2022 · Primary completion Nov 25, 2025
Drug: Neoantigen Peptides · For: Neoplasms
Sites: Tijuana, Mexico
Biogenea Pharmaceuticals Ltd.Biogen (BIIB)
NCT07285434 · 90 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 2, 2028
Drug: Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) · For: NSCLC (Non-small Cell Lung Cancer); Squamous Lung Cancer With FGFR1 Amplification; Non-Squamous Non Small Cell Lung Cancer
Sites: Thessaloniki, Greece
National Cancer Institute (NCI)NIH
NCT03606967 · 86 participants (planned) · Start Apr 13, 2021 · Primary completion Dec 30, 2026
Drug: Carboplatin; Durvalumab and 6 more · For: Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma
Sites: Orange, California; Sacramento, California; Aurora, Colorado · 30 sites in all
Centre Georges Francois LeclercAcademic, hospital or other
NCT07587827 · 77 participants (planned) · Start Nov 1, 2026 · Primary completion May 1, 2027
Drug: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) · For: Metastatic Colorectal Cancer (CRC); Locally Advanced Colorectal Cancer; Metastatic Pancreatic Cancer and 1 more
Sites: Besançon, France; Dijon, France
Washington University School of MedicineAcademic, hospital or other
NCT06529822 · 64 participants (planned) · Start Mar 20, 2025 · Primary completion Jan 31, 2030
Drug: Synthetic long peptide personalized cancer vaccine; Poly ICLC · For: Muscle-Invasive Bladder Carcinoma; Gastroesophageal Adenocarcinoma; Melanoma and 1 more
Sites: Orlando, Florida; St Louis, Missouri; Columbus, Ohio
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT02287428 · 56 participants (planned) · Start Nov 2014 · Primary completion Feb 2027
Drug: Personalized NeoAntigen Peptides; Pembrolizumab and 3 more · For: Glioblastoma
Sites: Boston, Massachusetts · 2 sites in all
- GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial CancerEnrolling by invitation
Biogenea Pharmaceuticals Ltd.Biogen (BIIB)
NCT07316361 · 40 participants (planned) · Start Feb 2, 2026 · Primary completion Dec 2, 2029
Drug: • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine · For: Endometrial Carcinoma; Endometrial Carcinoma Stage III
Sites: Thessaloniki, Greece
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.